Back to Results
First PageMeta Content
Drug discovery / Phosphoinositide 3-kinase inhibitor / Phosphoinositide 3-kinase / Histone deacetylase / AKT / Multiple myeloma / T cell / CD40 / Hematological malignancy / Medicine / Hematologic neoplasms / Lymphoma


DUAL FUNCTION HDAC AND PI3K INHIBITOR CUDC-907 AFFECTS CANCER CELLS AND THE TUMOR MICROENVIRONMENT IN HEMATOLOGICAL MALIGNANCIES Inc., Lexington, MA; 2Department of Medicine, Memorial Sloan-Kettering Cancer Center, New
Add to Reading List

Document Date: 2014-05-12 19:51:30

Open Document

File Size: 1,49 MB

Share Result on Facebook

City

Houston / Nashville / Lexington / San Diego / New York / /

Company

HEMATOLOGICAL MALIGNANCIES Inc. / Curis Inc. / /

Event

FDA Phase / /

Facility

Memorial Sloan-Kettering Cancer Center / Cannon Research Institute / R square Day / M.D. Anderson Cancer Center / /

IndustryTerm

culture media / chemical entity / treatment of patients with lymphoma / /

MedicalCondition

tumor / Best tumor / cancer / lymphoma / multiple myeloma / D. Clinical tumor / hematologic cancer / solid tumor / multiple myeloma cells / Hodgkin's lymphoma / hematologic malignancies / HRS Hodgkin’s lymphoma cells / hematologic cancers / L428 Hodgkin’s Lymphoma / B. Clinical tumor / Lymphoma Cell Line IC50 / /

MusicGroup

OPM / /

Organization

Leukemia & Lymphoma Society / 4Lymphoma and Myeloma Department / Memorial Sloan-Kettering Cancer Center / 3Sarah Cannon Research Institute / /

Product

CUDC-907 / /

ProvinceOrState

Tennessee / New York / California / Massachusetts / /

Technology

Alpha / antibodies / /

SocialTag